Lysergic acid diethylamide: evidence for stimulation of pituitary dopamine receptors.
Lysergic acid diethylamide (LSD), 0.05 mg/kg and 0.20 mg/kg, significantly decreased plasma prolactin (PRL) levels in male rats. LSD, 0.20 mg/kg, also inhibits the increase in plasma PRL levels produced by chlorpromazine (CPZ), 5 mg/kg, and alpha-methyl-paratyrosine (AMPT), 50 mg/kg, both of which interfere with dopaminergic inhibition of PRL secretion. LSD was more potent than methysergide, a serotonin receptor blocker, in lowering plasma PRL levels and more potent than apomorphine, a known direct acting dopamine agonist, in blocking the increase in plasma PRL produced by quipazine, a 5-HT agonist. These results suggest LSD has potent dopamine agonist properties on the rat pituitary or hypothalamic dopamine receptors which directly or indirectly inhibit PRL secretion.
D000818:Animals; D001058:Apomorphine / Q000494:pharmacology; D002746:Chlorpromazine / Q000494:pharmacology; D010134:Fenclonine / Q000494:pharmacology; D008238:Lysergic Acid Diethylamide / Q000494:pharmacology*; D008297:Male; D008781:Methyltyrosines / Q000494:pharmacology; D008784:Methysergide / Q000494:pharmacology; D010902:Pituitary Gland / Q000187:drug effects*; D011388:Prolactin / Q000097:blood; D011814:Quipazine / Q000494:pharmacology; D051381:Rats; D011954:Receptors, Dopamine / Q000187:drug effects*; D013268:Stimulation, Chemical
D008781:Methyltyrosines; D011954:Receptors, Dopamine; D011814:Quipazine; D008238:Lysergic Acid Diethylamide; D011388:Prolactin; D001058:Apomorphine; D010134:Fenclonine; D002746:Chlorpromazine; D008784:Methysergide